Stoke Therapeutics (STOK) announced that its board of directors has appointed Ian Smith as CEO. Smith has served as interim CEO since March and as a member of Stoke’s board of directors and advisor to the company since 2023. He will continue to serve as a director on the company’s board of directors. Arthur Tzianabos has been a member of the board of directors since 2018. He will resume his role as chairman of the board after serving as executive chairman while the CEO search was conducted.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Stoke, Biogen announce data from open-label extension studies of zorevunersen
- Biogen, Stoke presents data from Phase 1/2a, OLE studies of zorevunersen
- Promising Potential of Stoke Therapeutics: Buy Rating Supported by Positive Zorevunersen Data and Strategic Advancements
- Biogen, Stoke Therapeutics present data from studies of zorevunersen
- Stoke Therapeutics price target lowered to $28 from $29 at BTIG